Search

Your search keyword '"Barr, Paul"' showing total 125 results

Search Constraints

Start Over You searched for: Author "Barr, Paul" Remove constraint Author: "Barr, Paul" Database ScienceDirect Remove constraint Database: ScienceDirect
125 results on '"Barr, Paul"'

Search Results

2. Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL

7. Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study

11. Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

13. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

15. Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia

23. Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma

28. Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma

30. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL

32. Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912

33. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience

34. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma

35. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy

37. Postibrutinib outcomes in patients with mantle cell lymphoma

43. Final Analysis of the RESONATE-2 Study: Up to 10 Years of Follow-Up of First-Line Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

44. CLL-057 Outcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib (Ibr) + Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Up to 5.5 Years of Follow-Up in the Phase 2 CAPTIVATE Study

45. CLL-076 Final Analysis of the RESONATE-2 Study: up to 10 Years of Follow-Up of First-Line Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

46. CLL-495 Treatment Characteristics and Outcomes of Patients With Chronic/Small Lymphocytic Leukemia (CLL) Treated With Venetoclax and Bruton Tyrosine Kinase Inhibitor (BTKi) Combination Therapies

47. Treatment Characteristics and Outcomes of Patients With Chronic/Small Lymphocytic Leukemia (CLL) Treated With Venetoclax and Bruton Tyrosine Kinase Inhibitor (BTKi) Combination Therapies

48. Outcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib (Ibr) + Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Up to 5.5 Years of Follow-Up in the Phase 2 CAPTIVATE Study

50. Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2

Catalog

Books, media, physical & digital resources